Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea

Author:

Jo Kyung-Wook1,Kim Mihye2,Kim Ye-Jee3,Lee Hyun-Kyung4,Kim Hyun Kuk5,Jeon Doosoo6,Lyu Jiwon7,Park Hye Kyeong8,Mok Jeongha9,Kim Ju Sang10,Heo Eun Young11,Choi Sang Bong12,Yim Jae-Joon13,Shim Tae Sun1

Affiliation:

1. Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

2. Pulmonary, Allergy and Critical Care Medicine, Gangneung Asan Hospital, Gangneung, South Korea

3. Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, Seoul, South Korea

4. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, South Korea

5. Department of Pulmonary and Critical Care Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea

6. Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea

7. Division of Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea

8. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Ilsan, South Korea

9. Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea

10. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Incheon, South Korea

11. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea

12. Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea

13. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Abstract

No studies have investigated whether the discontinuation of ethambutol (EMB) based on susceptibility to isoniazid and rifampin, as determined by the GenoType MTBDRplus assay, would be appropriate. We aimed to determine the feasibility of discontinuing EMB before the end of the intensive phase of treatment based on the results of the MTBDRplus assay in patients with pulmonary tuberculosis (PTB).

Funder

Korean Institute of Tuberculosis

MOHW | Korea Centers for Disease Control & Prevention

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference23 articles.

1. Treatment of Drug Susceptible Pulmonary Tuberculosis

2. World Health Organization. 2009. Treatment of tuberculosis guidelines. http://www.who.int/tb/publications/2010/9789241547833/en/. Accessed 13 May 2019.

3. Trend of anti-tuberculosis drug resistance in Korea, 1994–2004;Bai GH;Int J Tuber Lung Dis,2007

4. Tuberculosis Treatment Guidelines Revised Committee. 2017. Korean tuberculosis treatment guidelines. http://www.lungkorea.org/bbs/index.html?code=guide&category=&gubun=&page=1&number=7563&mode=view&keyfield=&key=. Accessed 13 May 2019.

5. The Interval Between Initiation of Anti-tuberculosis Treatment in Patients with Culture-positive Pulmonary Tuberculosis and Receipt of Drug-susceptibility Test Results

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3